Member Info for silverhorse

Happy 2023 looking very positive - We all know looking back few years ago i predicted this hold firm i was saying . johnhume selling 3euros remember his still holds 40k so goodluck i did sell some planning to buy back but only got 10k 7.17euros - very good call myself and johnhume - GGP looking better john`s tip not a fan but hold some - UFO will be the winner 2023 over 1p - Can see this over 11euros this year so hold firm johnhume

2023 feels like the big 1 here - 2/3 times i was up 20k down 20k - this is the time for UFO run up to 3p for certain

We seems to be stuck around this 8p - FS ? Gold will hit 2.300 2023 Great year for gold/silver

Over 30p 2023 - lets see

Yes i listen to all the interviews - POLB 001 has previously been proven to be safe and well tolerated in a successful Phase I clinical trial, so the market is confused. But this now confirms that it is safe and well tolerated - He might have a point there i did expect more - likely will buy more i follow my gut my last winner up over 400%

Will these minnows with huge promises and valuable data be swallowed whole by big pharma, or allowed to blossom first?In summary, Poolbeg has a long cash runway, a strong portfolio with unique data, strong IP, with regulatory approval for its lead products. A capital-light model, and what appears to be encouraging drug discovery developments with AI partners, which brings the Company closer to the jackpot reward(s) that are out-licensing via big pharma

An LPS human challenge trial has been conducted over the past number of months, and recently completed with no serious adverse events – which is very positive to see. The full trial read-out of the unblinded data will be in Q2 2023.

POLB 001 has a long patent life, which is critical to pharma if they are to take the drug to phase III.

Investors are told to expect Data analysis and full data read-out is expected in Q2 2023. Investors appear to think the Company has kicked the can down the road. Yet, the board are in active discussions with potential license-out partners. Is it a case investor are playing it cautious due to the history of AIM Companies frequently being underwhelming?

Agree - I knew alot of that but very very good - i said before likely takeover! few months forward looking back here what a bargain 6.12p - Grant funding POLD003 other bits of update before the big news POLB001 Q2 - the share price will do same race ahead before at the moment sleeping

Any free shares for me?

It will all happen in 2023 - focus on the progress of the company not the poor share price 6p - am certain jeremy will top up again soon !

Cathal Friel -Spinning Poolbeg Pharma out of Hvivo (formerly known as Open Orphan) and getting Professor Luke O’Neill as non-executive director and scientific advisory board member changed everything. In my opinion, it is one of the most exciting and pivotal deals I’ll ever do, as I firmly believe Poolbeg Pharma could become a $1 billion pharmaceutical company.

It has a flu product which could help avoid future flu pandemics, oral vaccine technology, and an oral GLP-1 diabetes product which could become the most valuable obesity treatment in the world.

It also has the world’s largest repository of respiratory infectious disease progression data, and this data is invaluable for AI drug discovery programmes which Poolbeg is progressing.

jeremy skillington will probably buy more shares if this falls more

Eliminated class-associated tox issues
Short-term use of p38 for acute inflammation
overcomes tox concerns associated with long-term
treatment with p38 inhibitors for chronic
inflammatory conditions (e.g. Arthritis) I would say alot better for arthritis

Primarily focused on U.S and European markets for a strategic deal
Engaging early with select partners on POLB 001 ahead of initial LPS challenge data before
year end 2022 - maybe keep it quite when in talks !

Cutting Edge Data Analysis – Producing World Class Models - it will move us up

If only they said in that RNS results look on track very happy full results Q2- 2023

Why do you think the promised (POLB 001) results where helded back?

Hi cashintime - Hopefully tomorrow get us back up around 8p -

RYA not a fan of this stock but was thinking to take a small punt low 10 not 13 - is it worth it?